HRP20161742T1 - Soli i polimorfi od 8-fluoro-2-{4-[(metilamino)metil]fenil}-1,3,4,5-tetrahidro-6h-azepino[5,4,3-cd]indol-6-ona - Google Patents
Soli i polimorfi od 8-fluoro-2-{4-[(metilamino)metil]fenil}-1,3,4,5-tetrahidro-6h-azepino[5,4,3-cd]indol-6-ona Download PDFInfo
- Publication number
- HRP20161742T1 HRP20161742T1 HRP20161742TT HRP20161742T HRP20161742T1 HR P20161742 T1 HRP20161742 T1 HR P20161742T1 HR P20161742T T HRP20161742T T HR P20161742TT HR P20161742 T HRP20161742 T HR P20161742T HR P20161742 T1 HRP20161742 T1 HR P20161742T1
- Authority
- HR
- Croatia
- Prior art keywords
- salt
- salt according
- group
- camsylate
- ppm
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title claims 47
- HMABYWSNWIZPAG-UHFFFAOYSA-N rucaparib Chemical compound C1=CC(CNC)=CC=C1C(N1)=C2CCNC(=O)C3=C2C1=CC(F)=C3 HMABYWSNWIZPAG-UHFFFAOYSA-N 0.000 title claims 4
- 238000000634 powder X-ray diffraction Methods 0.000 claims 8
- 238000000371 solid-state nuclear magnetic resonance spectroscopy Methods 0.000 claims 8
- 238000001228 spectrum Methods 0.000 claims 8
- 239000000126 substance Substances 0.000 claims 8
- 238000000034 method Methods 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 241000124008 Mammalia Species 0.000 claims 4
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical class C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 claims 1
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 claims 1
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 150000002688 maleic acid derivatives Chemical class 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/19—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/145—Maleic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Gynecology & Obstetrics (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Claims (27)
1. Kamsilat-sol, naznačena time, da je od 8-fluoro-2-{4-[(metilamino)metil]fenil}-1,3,4,5-tetrahidro-6H-azepino[5,4,3-cd]indol-6-ona.
2. Sol prema zahtjevu 1, naznačena time, da sol je kristalna.
3. Sol prema zahtjevu 1, naznačena time, da je to kristalna bezvodna sol.
4. Sol prema bilo kojem od zahtjeva 1 do 3, naznačena time, da kamsilat je S-kamsilat.
5. Sol prema bilo kojem od zahtjeva 1 do 3, naznačena time, da kamsilat je R-kamsilat.
6. Sol prema bilo kojem od zahtjeva 1 do 5, naznačena time, da sol ima uzorak difrakcije praha X-zraka koji sadrži jednu ili više ili tri ili više ili tri vršne vrijednosti s difrakcijskim kutevima (2θ) odabranima iz skupine koja se sastoji od 12,2 ± 0,2, 14,8 ± 0,2 i 22,4 ± 0,2, pri čemu se navedeni uzorak rendgenske difrakcije praha dobiva uporabom bakar-K-α1-X-zraka valne duljine od 1,5406 Angstroma.
7. Sol prema bilo kojem od zahtjeva 1 do 6, naznačena time, da sol ima kruto stanje NMR spektra koje sadrži jedan ili više 13C-kemijskih pomaka odabranih iz skupine koja se sastoji od 213,4 ± 0,2, 171,8 ± 0,2 i 17,3 ± 0,2 ppm.
8. Sol prema bilo kojem od zahtjeva 1 do 7, naznačena time, da sol ima kruto stanje NMR spektra koje sadrži jedan ili više 19F-kemijskih pomaka odabranih iz skupine koja se sastoji od -118,9 ± 0,2 i -119,7 ppm ± 0,2.
9. Sol prema bilo kojem od zahtjeva 1 do 8, naznačena time, da sol ima uzorak difrakcije praha X-zraka koji sadrži jednu ili više ili tri ili više ili tri vršne vrijednosti s difrakcijskim kutevima (2θ) odabranima iz skupine koja se sastoji od 12,2 ± 0,2, 14,8 ± 0,2 i 22,4 ± 0,2, koji se dobiva uporabom bakar-K-α1-X-zraka valne duljine od 1,5406 Angstroma; gdje kruto stanje NMR spektra sadrži jedan ili više ili dva ili više ili tri 13C-kemijska pomaka odabrana iz skupine koja se sastoji od 213,4 ± 0,2, 171,8 ± 0,2 i 17,3 ± 0,2 ppm; i kruto stanje NMR spektra sadrži jedan ili više ili dva 19F-kemijska pomaka odabrana iz skupine koja se sastoji od -118,9 ± 0,2 i -119,7 ppm ± 0,2.
10. Sol prema bilo kojem od zahtjeva 1 do 9, naznačena time, da sol je bitno čisti polimorf od polimorfa S-kamsilat-oblik A.
11. Sol prema bilo kojem od zahtjeva 1 do 3, naznačena time, da sol je bitno čisti polimorf od polimorfa S-kamsilat-oblik B ili je bitno čisti polimorf od polimorfa S-kamsilat-oblik C.
12. Maleat-sol, naznačena time, da je od 8-fluoro-2-{4-[(metilamino)metil]fenil}-1,3,4,5-tetrahidro-6H-azepino[5,4,3-cd]indol-6-ona.
13. Sol prema zahtjevu 12, naznačena time, da sol je kristalna.
14. Sol prema zahtjevu 12, naznačena time, da sol je kristalna bezvodna sol.
15. Sol prema bilo kojem od zahtjeva 12 do 14, naznačena time, da sol ima uzorak difrakcije praha X-zraka koji sadrži vršne vrijednosti s difrakcijskim kutevima (2θ) od 6,0 ± 0,2, 20,3 ± 0,2 i 21,7 ± 0,2, pri čemu se navedeni uzorak rendgenske difrakcije praha dobiva uporabom bakar-K-α1-X-zraka valne duljine od 1,5406 Angstroma.
16. Sol prema bilo kojem od zahtjeva 12 do 15, naznačena time, da sol je bitno čisti polimorf od polimorfa maleat-oblik A.
17. Sol prema bilo kojem od zahtjeva 12 do 14, naznačena time, da sol ima uzorak difrakcije praha X-zraka koji sadrži vršne vrijednosti s difrakcijskim kutevima (2θ) od 7,5 ± 0,2, 11,3 ± 0,2 i 24,3 ± 0,2, pri čemu se navedeni uzorak rendgenske difrakcije praha dobiva uporabom bakar-K-α1-X-zraka valne duljine od 1,5406 Angstroma.
18. Sol prema bilo kojem od zahtjeva 12 do 14 i 17, naznačena time, da sol ima kruto stanje NMR spektra koje sadrži jedan ili više 13C-kemijskih pomaka odabranih iz skupine koja se sastoji od 171,3 ± 0,2, 112,4 ± 0,2 i 43,8 ± 0,2 ppm.
19. Sol prema bilo kojem od zahtjeva 12 do 14 i 17 do 18, naznačena time, da sol ima kruto stanje NMR spektra koje sadrži 19F-kemijski pomak na -123,1 ppm ± 0,2.
20. Sol prema bilo kojem od zahtjeva 12 do 14 i 17 do 19, naznačena time, da sol ima uzorak difrakcije praha X-zraka koji sadrži jednu ili više ili dvije ili više ili tri vršne vrijednosti s difrakcijskim kutevima (2θ) odabranima iz skupine koja se sastoji od 7,5 ± 0,2, 11,3 ± 0,2 i 24,3 ± 0,2, koji se dobiva uporabom bakar-K-α1-X-zraka valne duljine od 1,5406 Angstroma; gdje kruto stanje NMR spektra sadrži jedan ili više ili dva ili više ili tri 13C-kemijska pomaka odabrana iz skupine koja se sastoji od 171,3 ± 0,2, 112,4 ± 0,2 i 43,8 ± 0,2 ppm; i kruto stanje NMR spektra sadrži 19F-kemijski pomak na -123,1 ± 0,2 ppm.
21. Sol prema bilo kojem od zahtjeva 12 do 14 i 17 do 20, naznačena time, da sol je bitno čisti polimorf od polimorfa maleat-oblik B.
22. Farmaceutski sastav, naznačen time, da obuhvaća sol prema bilo kojem od zahtjeva 1 do 21.
23. Sol prema bilo kojem od zahtjeva 1 do 21, i farmaceutski sastav prema zahtjevu 22, naznačen/a time, da se upotrebljava u postupku liječenja bolesnih stanja kod sisavaca koja su posredovana putem djelovanja poli(ADP-riboza)-polimeraza, pri čemu postupak obuhvaća primjenu terapeutski učinkovite količine navedene soli ili navedenog farmaceutskog sastava, na sisavcu kojemu je to potrebno.
24. Sol prema bilo kojem od zahtjeva 1 do 21, i farmaceutski sastav prema zahtjevu 22, naznačen/a time, da se upotrebljava u postupku liječenja raka kod sisavaca, pri čemu postupak obuhvaća primjenu terapeutski učinkovite količine navedene soli ili navedenog farmaceutskog sastava, na sisavcu kojemu je to potrebno.
25. Uporaba soli prema bilo kojem od zahtjeva 1 do 21, naznačena time, da je za proizvodnju lijeka za liječenje raka.
26. Postupak, naznačen time, da se koristi za proizvodnju soli prema bilo kojem od zahtjeva 1 do 21.
27. Postupak prema zahtjevu 26, naznačen time, da sol je polimorfna sol i bitno je oslobođena od ostalih polimorfnih oblika od 8-fluoro-2-{4-[(metilamino)metil]fenil}-1,3,4,5-tetrahidro-6H-azepino[5,4,3-cd]indol-6-ona.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30427710P | 2010-02-12 | 2010-02-12 | |
EP11708094.5A EP2534153B2 (en) | 2010-02-12 | 2011-02-10 | Salts and polymorphs of 8-fluoro-2-{4-[(methylamino}methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one |
PCT/IB2011/050571 WO2011098971A1 (en) | 2010-02-12 | 2011-02-10 | Salts and polymorphs of 8-fluoro-2-{4-[(methylamino}methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one |
Publications (2)
Publication Number | Publication Date |
---|---|
HRP20161742T1 true HRP20161742T1 (hr) | 2017-02-24 |
HRP20161742T4 HRP20161742T4 (hr) | 2024-07-05 |
Family
ID=43859823
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20161742TT HRP20161742T4 (hr) | 2010-02-12 | 2011-02-10 | Soli i polimorfi od 8-fluoro-2-{4-[(metilamino)metil]fenil}-1,3,4,5-tetrahidro-6h-azepino[5,4,3-cd]indol-6-ona |
HRP20191944TT HRP20191944T1 (hr) | 2010-02-12 | 2019-10-25 | Soli i polimorfi od 8-fluoro-2-{4-[(metilamino)metil]fenil}-1,3,4,5-tetrahidro-6h-azepino[5,4,3-cd]indol-6-ona |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20191944TT HRP20191944T1 (hr) | 2010-02-12 | 2019-10-25 | Soli i polimorfi od 8-fluoro-2-{4-[(metilamino)metil]fenil}-1,3,4,5-tetrahidro-6h-azepino[5,4,3-cd]indol-6-ona |
Country Status (32)
Country | Link |
---|---|
US (5) | US8754072B2 (hr) |
EP (4) | EP2534153B2 (hr) |
JP (6) | JP5745283B2 (hr) |
KR (2) | KR20120127495A (hr) |
CN (2) | CN104876937B (hr) |
AR (2) | AR080164A1 (hr) |
AU (1) | AU2011213944B2 (hr) |
BR (1) | BR112012019050B1 (hr) |
CA (2) | CA2787881C (hr) |
CY (3) | CY1118319T1 (hr) |
DK (2) | DK2534153T4 (hr) |
ES (2) | ES2607806T5 (hr) |
FI (1) | FI2534153T4 (hr) |
HK (1) | HK1176617A1 (hr) |
HR (2) | HRP20161742T4 (hr) |
HU (3) | HUE030969T2 (hr) |
IL (1) | IL220921B (hr) |
LT (3) | LT2534153T (hr) |
LU (1) | LUC00093I2 (hr) |
MX (1) | MX343383B (hr) |
NL (1) | NL300958I2 (hr) |
NO (1) | NO2018039I1 (hr) |
NZ (1) | NZ601445A (hr) |
PL (2) | PL2534153T3 (hr) |
PT (2) | PT2534153T (hr) |
RS (2) | RS59494B1 (hr) |
RU (1) | RU2570198C2 (hr) |
SG (2) | SG182533A1 (hr) |
SI (2) | SI2534153T2 (hr) |
SM (1) | SMT201600462B (hr) |
TW (1) | TWI545123B (hr) |
WO (1) | WO2011098971A1 (hr) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8754072B2 (en) * | 2010-02-12 | 2014-06-17 | Pfizer Inc. | Salts and polymorphs of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one |
TW201516636A (zh) * | 2013-10-22 | 2015-05-01 | Hon Hai Prec Ind Co Ltd | 電子裝置及其供電方法 |
KR20170043597A (ko) * | 2014-08-22 | 2017-04-21 | 클로비스 온콜로지 인코포레이티드 | 루카파립의 고 용량 강도 정제 |
EP3476835A4 (en) | 2016-05-16 | 2020-01-01 | GB001, Inc. | QUINOLEIN DERIVATIVE CRYSTAL |
DE102016218772A1 (de) * | 2016-09-28 | 2018-03-29 | Bruker Biospin Gmbh | Verbesserte Temperierung eines NMR-MAS-Rotors |
EP3573990B1 (en) | 2017-01-24 | 2024-07-10 | Assia Chemical Industries Ltd. | Solid state forms of rucaparib and of rucaparib salts |
CN109651377B (zh) * | 2017-10-12 | 2020-10-20 | 成都海创药业有限公司 | 一种治疗癌症的化合物及其用途 |
CA3080657A1 (en) * | 2017-11-03 | 2019-05-09 | Sandoz Ag | Crystalline salt of a tricyclic poly(adp-ribose) polymerase inhibitor |
WO2019115000A1 (en) * | 2017-12-15 | 2019-06-20 | Advitech Advisory And Technologies Sa | Process for the preparation of rucaparib and novel synthesis intermediates |
WO2019130229A1 (en) | 2017-12-28 | 2019-07-04 | Mylan Laboratories Ltd | Methods and intermediates for preparing rucaparib |
TWI820077B (zh) | 2018-01-05 | 2023-11-01 | 美商斯布雷克薩一號公司 | 治療涉及酸性或缺氧性患病組織之疾病之化合物、組合物及方法 |
US10442813B2 (en) | 2018-01-30 | 2019-10-15 | RK Pharma Solutions LLC | Polymorphs of rucaparib camsylate and methods of making same |
WO2019207596A1 (en) | 2018-04-25 | 2019-10-31 | Mylan Laboratories Limited | Novel crystalline forms of rucaparib (s)-camsylate salt and rucaparib free base |
WO2019207498A1 (en) * | 2018-04-25 | 2019-10-31 | Biophore India Pharmaceuticals Pvt. Ltd | Solid forms of 8-fluoro-2-{4-[(methylamino)methyl] phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd] indol-6-one ((1s,4r)-7,7dimethyl-2-oxobicyclo [2.2.1] hept-1-yl) methanesulfonic acid salt (rucaparib camsylate) and the prerparation thereof |
CN108743557A (zh) * | 2018-06-27 | 2018-11-06 | 李莉 | 一种磷酸瑞卡帕布软胶囊及其制备方法 |
CN109111454A (zh) * | 2018-08-01 | 2019-01-01 | 宁波金未生物科技有限公司 | 一种瑞卡帕布s-樟脑磺酸盐 |
CN111217818A (zh) * | 2018-11-27 | 2020-06-02 | 台耀化学股份有限公司 | 芦卡帕尼樟脑磺酸盐的结晶、及制备三环化合物、芦卡帕尼及其樟脑磺酸盐结晶的方法 |
CN111542527A (zh) * | 2018-12-06 | 2020-08-14 | 上海诚妙医药科技有限公司 | 芦卡帕利樟脑磺酸盐的新晶型和制备方法及其用途 |
CA3146560A1 (en) | 2019-07-10 | 2021-01-14 | Cybrexa 2, Inc. | Peptide conjugates of cytotoxins as therapeutics |
MX2022000450A (es) | 2019-07-10 | 2022-04-25 | Cybrexa 3 Inc | Conjugados peptídicos de agentes dirigidos a microtúbulos como terapéuticos. |
CN111004244A (zh) * | 2019-12-27 | 2020-04-14 | 重庆市碚圣医药科技股份有限公司 | 一种瑞卡帕布樟脑磺酸盐的合成方法 |
WO2021156140A1 (en) | 2020-02-03 | 2021-08-12 | Sandoz Ag | Polymorph of rucaparib mesylate |
AU2021260109B2 (en) * | 2020-04-24 | 2024-07-11 | Astrazeneca Ab | Pharmaceutical formulations |
JP2023524212A (ja) | 2020-04-28 | 2023-06-09 | ライゼン ファーマシューティカルズ アーゲー | ポリ(adp-リボース)ポリメラーゼ(parp)阻害剤として有用な新規化合物 |
JP2023533982A (ja) | 2020-07-10 | 2023-08-07 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | Gas41阻害剤及びその使用方法 |
EP4182318A1 (en) | 2020-07-14 | 2023-05-24 | Assia Chemical Industries Ltd | Solid state forms of rucaparib salts |
WO2022090938A1 (en) | 2020-10-31 | 2022-05-05 | Rhizen Pharmaceuticals Ag | Phthalazinone derivatives useful as parp inhibitors |
TW202304447A (zh) | 2021-04-08 | 2023-02-01 | 瑞士商瑞森製藥公司 | 聚(adp-核糖)聚合酶抑制劑 |
WO2023137060A1 (en) | 2022-01-11 | 2023-07-20 | Assia Chemical Industries Ltd. | Solid state forms of rucaparib tosylate |
WO2023152754A1 (en) * | 2022-02-08 | 2023-08-17 | Sawant, Mohit Manikrao | Crystalline form of rosuvastatin allyl ester |
WO2024118070A1 (en) * | 2022-11-30 | 2024-06-06 | Ideaya Biosciences, Inc. | 2-oxoquinazoline crystalline forms |
Family Cites Families (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4489011A (en) | 1983-05-16 | 1984-12-18 | Merrell Dow Pharmaceuticals Inc. | Hypoglycemic N-(2-substituted-3-dialkylamino-2-propenylidene)-N-alkylalkanaminium camsylate salts |
GB8607683D0 (en) | 1986-03-27 | 1986-04-30 | Ici Plc | Anti-tumor agents |
GB8608335D0 (en) | 1986-04-04 | 1986-05-08 | Pfizer Ltd | Pharmaceutically acceptable salts |
GB8827305D0 (en) | 1988-11-23 | 1988-12-29 | British Bio Technology | Compounds |
DE4125292A1 (de) * | 1991-07-31 | 1993-02-04 | Kali Chemie Pharma Gmbh | 6-oxo-azepinoindol-verbindungen sowie verfahren und zwischenprodukte zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
AU675929B2 (en) | 1992-02-06 | 1997-02-27 | Curis, Inc. | Biosynthetic binding protein for cancer marker |
US6177401B1 (en) | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
US5455258A (en) | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
US5863949A (en) | 1995-03-08 | 1999-01-26 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
JP3053222B2 (ja) | 1995-04-20 | 2000-06-19 | ファイザー・インコーポレーテッド | Mmpおよびtnf抑制剤としてのアリールスルホニルヒドロキサム酸誘導体 |
US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
US5880141A (en) | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
GB9520822D0 (en) | 1995-10-11 | 1995-12-13 | Wellcome Found | Therapeutically active compounds |
GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
ES2183905T3 (es) | 1995-12-20 | 2003-04-01 | Hoffmann La Roche | Inhibidores de metaloproteasa de matriz. |
AU719327B2 (en) | 1996-03-05 | 2000-05-04 | Astrazeneca Ab | 4-anilinoquinazoline derivatives |
JP3195756B2 (ja) | 1996-07-04 | 2001-08-06 | 公子 吉水 | 潤滑補助体 |
EP0818442A3 (en) | 1996-07-12 | 1998-12-30 | Pfizer Inc. | Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor |
ID19609A (id) | 1996-07-13 | 1998-07-23 | Glaxo Group Ltd | Senyawa-senyawa heterosiklik |
ID19430A (id) | 1996-07-13 | 1998-07-09 | Glaxo Group Ltd | Senyawa senyawa heterosiklik |
HRP970371A2 (en) | 1996-07-13 | 1998-08-31 | Kathryn Jane Smith | Heterocyclic compounds |
DE69712496T2 (de) | 1996-07-18 | 2002-08-29 | Pfizer Inc., New York | Matrix metalloprotease-inhibitoren auf basis von phosphinsäuren |
IL128189A0 (en) | 1996-08-23 | 1999-11-30 | Pfizer | Arylsulfonylamino hydroxamic acid derivatives |
ID18494A (id) | 1996-10-02 | 1998-04-16 | Novartis Ag | Turunan pirazola leburan dan proses pembuatannya |
EP0950059B1 (en) | 1997-01-06 | 2004-08-04 | Pfizer Inc. | Cyclic sulfone derivatives |
ID22799A (id) | 1997-02-03 | 1999-12-09 | Pfizer Prod Inc | Turunan-turunan asam arilsulfonilamino hidroksamat |
BR9807824A (pt) | 1997-02-07 | 2000-03-08 | Pfizer | Derivados de n-hidróxi-beta-sulfonil-propionamida e seu uso como inibidores de metaloproteinases de matriz |
ID22809A (id) | 1997-02-11 | 1999-12-09 | Pfizer | Turunan-turunan asam arilsulfonil hidroksamat |
JP2002511852A (ja) | 1997-05-07 | 2002-04-16 | スージェン・インコーポレーテッド | 蛋白質キナーゼ活性の調節剤としての2−インドリノン誘導体 |
AU734009B2 (en) | 1997-05-30 | 2001-05-31 | Merck & Co., Inc. | Novel angiogenesis inhibitors |
US5835420A (en) | 1997-06-27 | 1998-11-10 | Aplus Flash Technology, Inc. | Node-precise voltage regulation for a MOS memory system |
ATE263147T1 (de) | 1997-08-08 | 2004-04-15 | Pfizer Prod Inc | Derivate von aryloxyarylsulfonylamino hydroxyaminsäuren |
WO1999010349A1 (en) | 1997-08-22 | 1999-03-04 | Zeneca Limited | Oxindolylquinazoline derivatives as angiogenesis inhibitors |
WO1999016755A1 (en) | 1997-09-26 | 1999-04-08 | Merck & Co., Inc. | Novel angiogenesis inhibitors |
CZ20001709A3 (cs) | 1997-11-11 | 2001-12-12 | Pfizer Products Inc. | Deriváty thienopyrimidu a thienopyridinu, farmaceutické kompozice a způsoby léčení na jejich bázi |
GB9725782D0 (en) | 1997-12-05 | 1998-02-04 | Pfizer Ltd | Therapeutic agents |
GB9800569D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
GB9800575D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
GB9801690D0 (en) | 1998-01-27 | 1998-03-25 | Pfizer Ltd | Therapeutic agents |
JP4462654B2 (ja) | 1998-03-26 | 2010-05-12 | ソニー株式会社 | 映像素材選択装置及び映像素材選択方法 |
PA8469401A1 (es) | 1998-04-10 | 2000-05-24 | Pfizer Prod Inc | Derivados biciclicos del acido hidroxamico |
PA8469501A1 (es) | 1998-04-10 | 2000-09-29 | Pfizer Prod Inc | Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico |
EP2020408B1 (en) | 1998-05-29 | 2013-06-26 | Sugen, Inc. | Pyrrole substituted 2-indolinone protein kinase inhibitor |
UA60365C2 (uk) | 1998-06-04 | 2003-10-15 | Пфайзер Продактс Інк. | Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця |
ES2213985T3 (es) | 1998-11-05 | 2004-09-01 | Pfizer Products Inc. | Derivados de hidroxiamida de acido 5-oxo-pirrolidin-2-carboxilico. |
US6649645B1 (en) | 1998-12-23 | 2003-11-18 | Pharmacia Corporation | Combination therapy of radiation and a COX-2 inhibitor for treatment of neoplasia |
JP2002533404A (ja) | 1998-12-23 | 2002-10-08 | ジー・ディー・サール・アンド・カンパニー | 新生物形成の治療における組合わせ療法としてインテグリン拮抗剤及び放射線治療を使用する方法 |
OA11749A (en) * | 1999-01-11 | 2005-07-19 | Agouron Pharma | Tricyclic inhibitors of poly(adp-ribose)polymerases. |
KR100452491B1 (ko) | 2001-03-29 | 2004-10-12 | 한미약품 주식회사 | 신규한 결정형 암로디핀 캠실레이트 염 및 그의 제조방법 |
KR20040011751A (ko) | 2002-07-30 | 2004-02-11 | 씨제이 주식회사 | 암로디핀의 유기산염 |
KR20050085835A (ko) † | 2002-12-19 | 2005-08-29 | 화이자 프로덕츠 인코포레이티드 | E-2-메톡시-n-(3-{4-[3-메틸-4-(6-메틸-피리딘-3-일옥시)-페닐아미노]-퀴나졸린-6-일}-알릴)-아세트아마이드의 착물, 및 그의 제조방법 및 용도 |
BRPI0408996A (pt) | 2003-03-31 | 2006-03-28 | Pfizer | saia de inibidores tricìclicos de poli(adpp-ribose) polimerases |
PL1660095T3 (pl) | 2003-07-25 | 2010-07-30 | Cancer Research Tech Ltd | Tricykliczne inhibitory PARP |
CN101384264B (zh) * | 2004-09-22 | 2012-03-14 | 辉瑞大药厂 | 含有聚(adp-核糖)聚合酶抑制剂的治疗组合物 |
KR100853601B1 (ko) * | 2004-09-22 | 2008-08-22 | 화이자 인코포레이티드 | 8-플루오로-2-{4-[(메틸아미노)메틸]페닐}-1,3,4,5-테트라하이드로-6H-아제피노[5,4,3-cd]인돌-6-온의포스페이트 염의 다형성 및 무정형 형태 |
NZ553295A (en) | 2004-09-22 | 2010-04-30 | Pfizer | Therapeutic combinations comprising poly(ADP-ribose) polymerases inhibitor |
CA2580833C (en) * | 2004-09-22 | 2010-12-21 | Pfizer, Inc. | Method of preparing poly(adp-ribose) polymerases inhibitors |
GB0502509D0 (en) | 2005-02-07 | 2005-03-16 | Pfizer Ltd | Novel salt form of a dopamine agonist |
KR20130129300A (ko) * | 2005-02-23 | 2013-11-27 | 테바 파마슈티컬 인더스트리즈 리미티드 | 함량 균일성이 개선된 라사길린 제형 |
CN101528202A (zh) * | 2006-07-05 | 2009-09-09 | 特瓦制药工业有限公司 | 美金刚的药物组合物 |
KR100843401B1 (ko) | 2006-12-04 | 2008-07-04 | 씨제이제일제당 (주) | 결정성 s-(-)-암로디핀 캠실레이트 무수물 및 이의제조방법 |
CN103923169B (zh) * | 2006-12-06 | 2017-05-24 | 科内图斯医药公司 | (3s)‑3‑[n‑(n’‑(2‑叔丁基苯基)草氨酰基)丙氨酰基]氨基‑5‑(2’,3’,5’,6’‑四氟苯氧基)‑4‑氧代戊酸的结晶形式 |
WO2008114114A2 (en) * | 2007-03-16 | 2008-09-25 | Pfizer Products Inc. | Poly(adp-ribose) polymerases inhibitor for treating ophthalmic condition |
EP2065385A1 (en) | 2007-11-28 | 2009-06-03 | Laboratorios SALVAT, S.A. | Stable crystalline salt of (R)-3-fluorophenyl-3,4,5-trifluorobenzylcarbamic acid 1-azabiciyclo [2.2.2]oct-3-yl ester |
JP2011506315A (ja) * | 2007-12-05 | 2011-03-03 | バイアル−ポルテラ アンド シーエー,エス.エー. | 新たな塩、及び結晶形 |
KR20090060674A (ko) | 2007-12-10 | 2009-06-15 | 씨제이제일제당 (주) | 결정형의 지프라시돈 술폰산염, 그 제조방법, 및 그것를포함하는 약제학적 조성물 |
RU2495035C2 (ru) | 2008-01-08 | 2013-10-10 | Мерк Шарп Энд Домэ Лтд | Фармацевтически приемлемые соли 2-{4-[(3s)-пиперидин-3-ил]фенил}-2н-индазол-7-карбоксамида |
SG173002A1 (en) | 2009-01-17 | 2011-08-29 | Boomerang Systems Inc | Automated storage system and transport vehicle |
US8754072B2 (en) | 2010-02-12 | 2014-06-17 | Pfizer Inc. | Salts and polymorphs of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one |
US9539930B2 (en) | 2011-09-23 | 2017-01-10 | Gentex Corporation | Systems and methods for rear view mirror displays |
CN104053696B (zh) | 2011-12-26 | 2015-07-08 | 胜技高分子株式会社 | 聚对苯二甲酸丁二醇酯树脂颗粒、以及该聚对苯二甲酸丁二醇酯树脂颗粒的制造方法 |
US9384339B2 (en) | 2012-01-13 | 2016-07-05 | Telecommunication Systems, Inc. | Authenticating cloud computing enabling secure services |
US10181126B2 (en) | 2012-03-13 | 2019-01-15 | American Express Travel Related Services Company, Inc. | Systems and methods for tailoring marketing |
KR101984831B1 (ko) | 2013-01-31 | 2019-05-31 | 삼성전자 주식회사 | 반도체 패키지 및 그 제조 방법 |
CN103309115B (zh) | 2013-05-30 | 2016-03-23 | 京东方科技集团股份有限公司 | 彩色电泳显示面板及其制造方法、显示装置 |
US9501163B2 (en) | 2014-05-06 | 2016-11-22 | Symbol Technologies, Llc | Apparatus and method for activating a trigger mechanism |
US10884952B2 (en) | 2016-09-30 | 2021-01-05 | Intel Corporation | Enforcing memory operand types using protection keys |
JP6943759B2 (ja) | 2017-12-28 | 2021-10-06 | 株式会社東海理化電機製作所 | シフト装置 |
-
2011
- 2011-02-10 US US13/522,549 patent/US8754072B2/en active Active
- 2011-02-10 MX MX2012008911A patent/MX343383B/es active IP Right Grant
- 2011-02-10 HU HUE11708094A patent/HUE030969T2/en unknown
- 2011-02-10 HR HRP20161742TT patent/HRP20161742T4/hr unknown
- 2011-02-10 BR BR112012019050-4A patent/BR112012019050B1/pt not_active IP Right Cessation
- 2011-02-10 KR KR1020127023813A patent/KR20120127495A/ko active Search and Examination
- 2011-02-10 EP EP11708094.5A patent/EP2534153B2/en active Active
- 2011-02-10 EP EP19178840.5A patent/EP3597651A1/en not_active Withdrawn
- 2011-02-10 RU RU2012138892/04A patent/RU2570198C2/ru active
- 2011-02-10 ES ES11708094T patent/ES2607806T5/es active Active
- 2011-02-10 CN CN201410818193.1A patent/CN104876937B/zh active Active
- 2011-02-10 PL PL11708094T patent/PL2534153T3/pl unknown
- 2011-02-10 PT PT117080945T patent/PT2534153T/pt unknown
- 2011-02-10 EP EP22199074.0A patent/EP4166558A1/en active Pending
- 2011-02-10 DK DK11708094.5T patent/DK2534153T4/da active
- 2011-02-10 RS RS20191394A patent/RS59494B1/sr unknown
- 2011-02-10 ES ES16183844T patent/ES2753748T3/es active Active
- 2011-02-10 SI SI201131051T patent/SI2534153T2/sl unknown
- 2011-02-10 PT PT161838446T patent/PT3150610T/pt unknown
- 2011-02-10 SG SG2012052171A patent/SG182533A1/en unknown
- 2011-02-10 CA CA2787881A patent/CA2787881C/en active Active
- 2011-02-10 PL PL16183844T patent/PL3150610T3/pl unknown
- 2011-02-10 SG SG10201406805RA patent/SG10201406805RA/en unknown
- 2011-02-10 KR KR1020197005968A patent/KR102108226B1/ko active IP Right Grant
- 2011-02-10 LT LTEP11708094.5T patent/LT2534153T/lt unknown
- 2011-02-10 EP EP16183844.6A patent/EP3150610B1/en active Active
- 2011-02-10 RS RS20161117A patent/RS55487B2/sr unknown
- 2011-02-10 JP JP2011026718A patent/JP5745283B2/ja active Active
- 2011-02-10 AU AU2011213944A patent/AU2011213944B2/en active Active
- 2011-02-10 CA CA3024216A patent/CA3024216C/en active Active
- 2011-02-10 DK DK16183844T patent/DK3150610T3/da active
- 2011-02-10 NZ NZ601445A patent/NZ601445A/en unknown
- 2011-02-10 LT LT16183844T patent/LT3150610T/lt unknown
- 2011-02-10 HU HUE16183844A patent/HUE047248T2/hu unknown
- 2011-02-10 SI SI201131808T patent/SI3150610T1/sl unknown
- 2011-02-10 CN CN201180009237.0A patent/CN102884066B/zh active Active
- 2011-02-10 WO PCT/IB2011/050571 patent/WO2011098971A1/en active Application Filing
- 2011-02-11 AR ARP110100427A patent/AR080164A1/es not_active Application Discontinuation
- 2011-02-11 TW TW100104676A patent/TWI545123B/zh active
-
2012
- 2012-07-12 IL IL220921A patent/IL220921B/en active IP Right Grant
-
2013
- 2013-03-28 HK HK13103915.1A patent/HK1176617A1/zh unknown
-
2014
- 2014-05-08 US US14/272,589 patent/US9045487B2/en active Active
-
2015
- 2015-04-21 JP JP2015086722A patent/JP6013551B2/ja active Active
- 2015-04-28 US US14/698,463 patent/US9861638B2/en active Active
-
2016
- 2016-09-21 JP JP2016183846A patent/JP6371350B2/ja active Active
- 2016-12-13 CY CY20161101288T patent/CY1118319T1/el unknown
- 2016-12-21 SM SM201600462T patent/SMT201600462B/it unknown
-
2017
- 2017-08-16 AR ARP170102290A patent/AR109356A2/es unknown
- 2017-12-06 US US15/833,073 patent/US10278974B2/en active Active
-
2018
- 2018-07-12 JP JP2018132270A patent/JP6640931B2/ja active Active
- 2018-11-13 CY CY2018031C patent/CY2018031I2/el unknown
- 2018-11-13 LU LU00093C patent/LUC00093I2/fr unknown
- 2018-11-14 HU HUS1800046C patent/HUS1800046I1/hu unknown
- 2018-11-15 NO NO2018039C patent/NO2018039I1/no unknown
- 2018-11-15 LT LTPA2018517C patent/LTC2534153I2/lt unknown
- 2018-11-16 FI FIEP11708094.5T patent/FI2534153T4/fi active
- 2018-11-19 NL NL300958C patent/NL300958I2/nl unknown
-
2019
- 2019-02-28 US US16/288,615 patent/US20200000821A1/en not_active Abandoned
- 2019-10-25 HR HRP20191944TT patent/HRP20191944T1/hr unknown
- 2019-10-31 CY CY20191101132T patent/CY1122218T1/el unknown
- 2019-12-26 JP JP2019235421A patent/JP2020050671A/ja not_active Withdrawn
-
2021
- 2021-05-06 JP JP2021078485A patent/JP2021107460A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20161742T1 (hr) | Soli i polimorfi od 8-fluoro-2-{4-[(metilamino)metil]fenil}-1,3,4,5-tetrahidro-6h-azepino[5,4,3-cd]indol-6-ona | |
JP2016065042A5 (hr) | ||
HRP20181048T1 (hr) | Neuroaktivni 19-alkoksi-17-supstituirani steroidi, korisni u postupcima liječenja | |
EA201791941A1 (ru) | Бициклические кетосульфонамидные соединения | |
EA201692095A1 (ru) | Имидазо[4,5-c]хинолин-2-оновые соединения и их применение в лечении рака | |
HRP20160030T1 (hr) | Derivati 6,7-dihidro-pirazolo[1,5-a]pirazin-4-ilamina koji su korisni kao inhibitori beta-sekretaze (bace) | |
EA201391032A1 (ru) | Новые гетероциклические производные и их применение в лечении неврологических расстройств | |
RU2014110399A (ru) | Кристаллические формы вгс протеазного ингибитора | |
WO2009016410A3 (en) | Chemical compounds 831 | |
MA33838B1 (fr) | Forme amorphe et cristalline de l'hémitartrate de genz 112638 au titre d'inhibiteur de la glucosylcéramide synthétase | |
WO2012096929A3 (en) | Heteroaryl compounds and methods of use thereof | |
JP2016503010A5 (hr) | ||
RU2014109676A (ru) | Твердые формы ингибитора диссоциации транстиретина | |
JP2014526498A5 (hr) | ||
SI2796458T1 (en) | CRYSTALINIC SODIUM RALTEGRAVIR SOLUTIONS | |
HRP20201470T1 (hr) | Oblici soli nilotiniba u krutom stanju | |
CU20170158A7 (es) | Derivados sustituidos de 1-arilnaftiridina-3-carboxamidas y su utilidad en el tratamiento o prevención de enfermedades cardiovasculares y renales | |
BR112019008295A2 (pt) | composto inibidor de multiquinase, e forma cristalina e utilização do mesmo | |
JP2015522037A5 (hr) | ||
WO2013177534A3 (en) | New salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof | |
FI3713942T3 (fi) | 4-(4-(1-isopropyyli-7-okso-1,4,6,7-tetrahydrospiro[indatsoli-5,4'-piperidiini]-1'-karbonyyli)-6-metoksipyridin-2-yyli)bentsoehapon kiteinen 2-amino-2-(hydroksimetyyli)propaani-1,3-diolisuola | |
WO2014014794A3 (en) | Mineralocorticoid receptor antagonists | |
WO2013117503A3 (en) | Pi3k inhibitors for treating fibrotic diseases | |
HRP20151340T1 (hr) | Derivati tieno[2,3-d] pirimidina i njihova primjena u lijeäśenju aritmije | |
WO2013043744A3 (en) | Tricyclic compounds useful as neurogenic and neuroprotective agents |